Overview

A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
0
Participant gender:
All
Summary
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Tacrolimus
Tofacitinib
Criteria
Inclusion Criteria:

- Recipient of a first-time kidney transplant

- Between the ages of 18 and 70 years, inclusive

Exclusion Criteria:

- Recipient of any non-kidney transplant